Iterum Therapeutics plc (ITRM) Earnings History
Net Loss9 years of earnings data (2016–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Iterum Therapeutics plc (ITRM) Earnings Overview
As of June 30, 2026, Iterum Therapeutics plc (ITRM) reported trailing twelve-month net income of -$27M, reflecting +57.4% year-over-year growth. The company earned $-0.59 per diluted share over the past four quarters.
Looking at the long-term picture, ITRM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2016.
Iterum Therapeutics plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), NKTR (-$158M net income, -297.1% margin), SPRO ($15M net income, 14.4% margin), ITRM has comparable earnings metrics. Compare ITRM vs PRAX →
ITRM Earnings vs Peers
Earnings metrics vs comparable public companies
ITRM Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$25M | +35.4% | -$19M | $-1.26 | - | - |
| 2023 | -$38M | +13.6% | -$47M | $-2.96 | - | - |
| 2022 | -$44M | +51.5% | -$30M | $-3.63 | - | - |
| 2021 | -$92M | -76.1% | -$25M | $-8.41 | - | - |
| 2020 | -$52M | +49.6% | -$32M | $-32.49 | - | - |
| 2019 | -$103M | -33.8% | -$102M | $-7.10 | -278729.7% | -275732.4% |
| 2018 | -$77M | -162.0% | -$77M | $-98.32 | -8867.2% | -8810.0% |
| 2017 | -$29M | -118.4% | -$29M | $-58.08 | -5788.6% | -5798.2% |
| 2016 | -$13M | - | -$13M | $-26.59 | - | - |
Download Data
Export ITRM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ITRM — Frequently Asked Questions
Quick answers to the most common questions about buying ITRM stock.
What is ITRM earnings per share (EPS)?
ITRM trailing twelve-month (TTM) diluted EPS is $-0.59, reflecting +57.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2024 is available in the table on this page.
What is Iterum Therapeutics plc's net income?
Iterum Therapeutics plc (ITRM) trailing twelve-month net income is $-27M as of 2024. Earnings grew +57.4% year-over-year.
Is ITRM profitable?
ITRM is not currently profitable on a TTM basis, reporting a net loss of $-27M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ITRM's earnings growth rate?
ITRM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2024.
What are ITRM's profit margins?
Iterum Therapeutics plc net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is ITRM growing earnings?
Yes, ITRM earnings are accelerating — EPS growth of +57.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-27M. Earnings momentum is strengthening.
What was ITRM's best earnings year?
Iterum Therapeutics plc's highest annual net income on record is $-13M, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2024 and includes all annual and quarterly figures.
What were ITRM's earnings last quarter?
ITRM's most recent reported quarter was Q3 2025. Net income was $-9M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.